HCPCS Code Q5119: Injection, Rituximab-pvvr, Biosimilar (Ruxience), 10 mg

Ruxience is rituximab-pvvr, a biosimilar to Rituxan with highly similar safety and effectiveness for the approved reference indications when payer policy allows. They are billed differently.

Bill 38 units on the administered line because Q5119 is per 10 mg and claims use whole units. If any drug was discarded, add a second line with modifier JW for the wasted amount so the total units equal the amount prepared from the vial(s). If no waste occurred, append JZ to the administered line.

Yes. Payers set diagnosis-specific frequency and cycle rules for follicular lymphoma, diffuse large B-cell disease, mantle cell lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. Verify prior authorization and schedule requirements before each cycle to ensure continued coverage.